Form 4: Adicet Bio Director Carl L. Gordon Reports Acquisition of Restricted Stock Units and Stock Options

Director Carl L. Gordon reports acquisition of restricted stock units and stock options in Adicet Bio, Inc.

Summary

• On June 5, 2024, Carl L. Gordon, a director of Adicet Bio, Inc., reported the acquisition of 5,900 shares of common stock through Restricted Stock Units (RSUs) and 26,400 stock options.
• The RSUs vest fully on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service on the board.
• The stock options, with an exercise price of $1.44, also vest fully under the same conditions as the RSUs and expire on June 4, 2034.
• Gordon also indirectly holds shares through various OrbiMed entities, including OrbiMed Private Investments V, LP (7,526,359 shares), OrbiMed Private Investments VI, LP (990,254 shares), OrbiMed Genesis Master Fund, L.P. (1,255,985 shares), OrbiMed Israel Partners Limited Partnership (1,027,885 shares), and OrbiMed Israel Partners II, L.P. (646,657 shares).
• Gordon disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The acquisition of shares and options by a director can be seen as a positive sign, but it's not overwhelmingly so.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
• The vesting conditions tied to continued service on the board align the director's interests with those of the shareholders.

Future Outlook

The vesting of RSUs and stock options is contingent upon continued service on the board, suggesting an ongoing commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The reported transactions provide shareholders with insights into the director's holdings and alignment with company performance.

Key Dates